Phase 3 N=145 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Head and Neck Cancer
Primary: Overall Survival — 73; 78 percent of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=505 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -10.7; -15.4; -15.4 units on a scale — p=<0.001
Phase 3 N=264 Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14 — 21; 54 Number of participants — p=<0.001
Phase 3 N=114 PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
Chronic Hepatitis C
Primary: Sustained Viral Response (SVR) — 29; 12 participants
Phase 3 N=826 A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
Atrophy · Vaginal Diseases
Primary: Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal Dryness — -1.22; -1.26; -0.84 Units on a scale
Phase 3 N=919 Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
Atrophy · Vaginal Diseases
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dryness Strata) — -3.7; -31.7 percentage of parabasal cells
Phase 3 N=511 A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 — 23.3; 54.5; 50.6 percentage of participants
Phase 3 N=180 Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
Atrophy · Vaginal Diseases
Primary: Incidence of Adverse Events (AEs) — 38; 44; 22; 11 Participants
Phase 3 N=301 Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
Atrophy · Vaginal Diseases
Primary: Incidence of Adverse Events (AEs) — 220; 67; 34; 13 Participants
Phase 3 N=426 A Clinical Study to Evaluate the Safety of Ospemifene
Atrophy · Vaginal Diseases
Primary: Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal Smear — 5.0; -46.0 percentage of parabasal cells
Phase 3 N=480 Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
Type 2 Diabetes Mellitus
Primary: Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30 — -0.32; -0.51 Percentage of HbA1c
Phase 3 N=142 An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain
Chronic Pain
Primary: Questionnaire of Opioid Withdrawal Symptoms — 137; 2; 1; 0 participants
Phase 3 N=201 Evaluating Improvement Strategies in Addiction Treatment
Addiction
Primary: Change in Average Waiting Time From First Contact to Treatment — .253; 4.610; 4.723; 3.520 Change in days
Phase 3 N=881 Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Diphtheria · Tetanus · Pertussis
Primary: Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~T — 91.1; 127; 69.2; 127 Titers
Phase 3 N=1,169 An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001